Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 11/20 | 0.43 |
| ▸ | PDE4A | P27815 | 8/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.43 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402862 | 0.82 | PDE4B (0.46) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL28164154 | 0.82 | PDE4B (0.43) | PDE4BPDE4APDE4DPDE4CRIPK1 | |
| SCHEMBL874503 | 0.82 | PDE4D (0.41) | PDE4BPDE4APDE4DPDE4CRIPK1 | |
| SCHEMBL16961866 | 0.80 | MEN1 (0.44) | PTPN1SLC6A4 | |
| SCHEMBL29994875 | 0.78 | PDE4B (0.53) | PDE4BPDE4APDE4DPDE4CRIPK1 | |
| SCHEMBL18830718 | 0.78 | PDE4B (0.53) | PDE4BPDE4APDE4DPDE4CRIPK1 | |
| SCHEMBL4594035 | 0.77 | PDE4B (0.45) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL2584860 | 0.76 | PDE4B (0.39) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL16960164 | 0.74 | KCNN4 (0.37) | PTPN1HTR1ASLC6A4 | |
| SCHEMBL24153922 | 0.73 | RIPK1 (0.47) | RIPK1HTR1ASLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8933073-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2015-01-13 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8865662-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8445451-B2 | Macrolides and uses of macrolides | BASILEA PHARMACEUTICA AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| WO-2011018510-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-02-17 | — | — | WO | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009098320-A2 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277174-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4D 6/4885 |
| US-20140142100-A1 | NEW MACROLIDES AND THEIR USE | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4A 1/4885PDE4D 5/4885 |
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4B 2412/4885PDE4A 1873/4885PDE4D 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.